The art and science of running a successful pharmaceutical company.
March 17, 2010
By:George Koroneos
A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity?
 |
 | March 1, 2010
Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?
|
 | March 1, 2010
By:Walter Armstrong
Several leading pharmas may already have a drug for a retrovirus linked to chronic fatigue disease. Has medicine's "problem child" finally earned the industry's respect?
|
March 1, 2010
In a digital world, vast quantities of data at hand are a powerful asset. Managing that information is key to seizing competitive advantage.
|
February 17, 2010
By: Oriana Schwindt
The company released its numbers for 4Q '09, but is still hunting for more annual savings, which could come in the form of up to 15,000 job cuts.
|
February 10, 2010
By:George Koroneos
The blockbuster model has been dead for a while, but pharma is just now researching new ways to reach patients. Pharm Exec interviews Carolyn Luce at Ernst & Young to learn more about the new era of pharma outreach and marketing.
|
February 3, 2010
By:George Koroneos, Online Content & News Editor
Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast.
|
| 
PharmExec Blog
Follow Us
RSS
Bookstore
The New Health is the fast-morphing world of biopharma: emerging science, changing technology, rising costs, global regulations. The New Health needs an ally. More at www.quintiles.com/newhealth.
What's the best managed pharma? Professor Bill Trombetta of Saint Joseph's University attempts to answer the question in Pharm Exec's Industry Audit.
The most respected annual ranking of top 50 pharmaceutical companies by prescription drug sales... Who's in, who's back, and who's out?